Search results
Results from the WOW.Com Content Network
Myostatin inhibitors were generally able to increase lean body mass and reduce body fat in people with sarcopenia, but the extent to which this translated into functional improvements varied. [ 11 ] Bimagrumab showed effectiveness in increasing lean mass and reducing fat mass in obese individuals in a clinical trial.
Myostatin is a myokine that is produced and released by myocytes and acts on muscle cells to inhibit muscle growth. [7] Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family. [8] [9] Myostatin is assembled and produced in skeletal muscle before it is released into the blood stream. [10]
Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin. [ 3 ] Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin ...
In April 2016, Novartis announced that bimagrumab had failed a Phase IIb/III study for sporadic inclusion body myositis. [6] In January 2021, a new study confirmed that treatment with Bimagrumab is safe and effective for treating excess adiposity and metabolic disturbances of adult patients with obesity and type 2 diabetes. [ 7 ]
Sarcopenic obesity is a combination of two disease states, sarcopenia and obesity.Sarcopenia is the muscle mass/strength/physical function loss associated with increased age, [1] and obesity is based off a weight to height ratio or body mass index (BMI) that is characterized by high body fat or being overweight.
Apitegromab (SRK-015) is a fully human monoclonal antibody developed to treat spinal muscular atrophy.It works by binding to and inhibiting promyostatin, a precursor to myostatin, which limits the size of skeletal muscle tissue, as well as inactive myostatin.
Orlistat (Xenical), the most commonly used medication to treat obesity and sibutramine (Meridia), a medication that was withdrawn due to cardiovascular side effects. Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat.
Myostatin-related muscle hypertrophy is a rare genetic condition characterized by reduced body fat and increased skeletal muscle size. [1] Affected individuals have up to twice the usual amount of muscle mass in their bodies, but increases in muscle strength are not usually congruent. [ 2 ]